Podcast appearances and mentions of mark humayun

Dr. Rajesh Rao dives deep into world of retinal implants with author Dr. Mark Humayun from his Ophthalmology Retina article, “Advanced Retina Implants.” Don't miss Ophthalmology Podcast Live! at the Technology Pavilion during AAO 2022. Advanced Retina Implants. Humayun, Mark S. et al. Ophthalmology Retina. In Press.

In this episode of The Stem Cell Report, Martin Pera is joined by three experts on the eye, its development, and disease processes.  Dr. Mark Humayun is the Director of the Institute for Biomedical Therapeutics and Co-Director of the Roski Eye Institute at the University of Southern California.  Dr. Anand Swaroop is a Senior Investigator in the Neurobiology, Neurodegeneration and Repair Laboratory at the National Eye Institute, and Dr. Masayo Takahashi is a pioneer in iPS-based approaches to treat eye disease and the President of Vision Care Inc., a venture that will focus on cell-based treatments for macular degeneration and other eye diseases. Today's guests will talk about their respective research and where the field of regenerative medicine for eye disease currently stands and where it is headed. Articles from the guests can be found below in the “Supporting Docs” as is the Virtual Collection of eye-focused papers recently published in Stem Cell Reports.  GuestsMark Humayun, MD, PhD, Keck School of Medicine, University of Southern California, USA Anand Swaroop, PhD, National Institutes of Health, USA Masayo Takahashi, MD, PhD, Vision Care Inc., Japan HostMartin Pera, PhD – Editor-in-Chief, Stem Cell Reports and The Jackson LaboratoryTwitter: @martinperaJAXSupporting DocumentsSurvival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration, Stem Cell Reports Gene therapy of dominant CRX-Leber Congenital Amaurosis using patient derived Retinal Organoids, Stem Cell Reports Stem cells in translation: Eye disease, Stem Cell Reports Virtual Collection  About Stem Cell ReportsStem Cell Reports is the Open Access journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians.Twitter: @StemCellReportsAbout ISSCRWith nearly 4,000 members from more than 65 countries, the International Society for Stem Cell Research is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health.Twitter: @ISSCRAcknowledgementsISSCR StaffKeith Alm, Chief Executive OfficerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsJack Mosher, Scientific AdvisorVoice WorkBen SnitkoffMusic@Konovalov

It seems like science fiction to restore the sight of a person who has been blind for years, but innovations in the field of retina have made the impossible possible. On this episode of ASRS's Retina Health for Life, Dr. Timothy Murray is joined by the co-inventor of the artificial retina Dr. Mark Humayun, co-Director of USC's Roski Eye Institute and a world-renowned expert on vision restoration. Drs. Humayun and Murray discuss the development of this technological breakthrough, which has helped people with certain inherited retinal conditions almost miraculously regain some of their sight.Resources: Access a downloadable fact sheet about retinitis pigmentosa and retinal prosthesis at www.asrs.org/patients/retinal-diseases/8/retinitis-pigmentosa-and-retinal-prosthesis.

This podcast is about big ideas on how technology is making life better for people with vision loss. Today's big idea is all about the cutting edge advancements in ocular bionic prosthetics. The Argus II is a device that uses a camera and a chip to stimulate the retina and send signals to the brain. Our guest, Dr. Mark Humayun, developer of the Argus II, speaks with Dr. Roberts about the development of this device, and the importance of the collaboration between developers and early adopters. He talks about the engineering, neurophysiology, and surgical challenges they've overcome to get to where they are, as well as what kind of advancements might be possible in the future.   The Big Takeaways: The Argus II is a device with two components: a wearable component that consists of glasses with a camera and video processing unit and an implanted device that includes an antenna and an electronic chip that sends electrodes to stimulate the remaining cells of the retina. The visual system is similar to a computer in that it requires hardware (our eyes, retina, optic nerve, visual cortex) and software (converts signals to what we describe as sight). When developing artificial vision, Dr. Humayun had to pinpoint how much of the retina needed to be replaced, as well as how much of the retina needed to still exist for the device to work. The electronic system stimulates groups of neurons into visual perceptions. Users of the Argus II can currently perceive up to 10 shades of gray. Dr. Humayun and his team are working on getting the device to generate color vision by stimulating the retina at different frequencies, which the wearer learns to associate with a named color. The cochlear implant was a big influence on the initial development of Argus II — they reconfigured a cochlear implant and used it to stimulate the retina rather than the cochlea. As they reconfigure and continue to develop the device, the collaboration between actual users and developers is crucial. Now that they have the hardware and technology, they can focus on future developments like an implant that bypasses the optic nerve and sends electrodes directly to the visual cortex.   Tweetables: “I've been so lucky my whole adult life to have that collaborative experience with everyone who's ever built legs for me.” — Aimee Mullins, actor, athlete, public speaker, and double amputee “The most emotional thing for me was being able to see letters again. That was such an emotional experience, I don't know how to put it into words.” — Barbara Campbell, Argus II implant recipient “You can think of it like this, that it wirelessly connects the blind person to a camera, and jumpstarts the otherwise blind eye and sends the information to the brain.” — Dr. Mark Humayun “There are some features that are different than our human eye, there are some advantages, but clearly our human eye is incredibly, exquisitely engineered to give you a very pristine, refined, and high-resolution image.” — Dr. Mark Humayun   Contact Us: Contact us at podcasts@lighthouseguild.org with your innovative new technology ideas for people with vision loss.   Pertinent Links: Lighthouse Guild Argus II   Guest Bio: Dr. Mark Humayun Mark S. Humayun, MD, PhD, is Director, USC Ginsburg Institute for Biomedical Therapeutics and Co-Director, USC Roski Eye Institute. Dr. Humayan received his Bachelor of Science degree from Georgetown University in 1984, his Master's Doctorate from Duke University in 1989, and his PhD from the University of North Carolina, Chapel Hill in 1994. He completed his ophthalmology residency at Duke Eye Center and fellowships in both vitreoretinal and retinovascular surgery at Johns Hopkins Hospital. He stayed on as faculty at Johns Hopkins where he rose to the rank of associate professor before moving to USC in 2001. Dr. Humayun has devoted much of his career to clinical and scientific research in ophthalmology and bioengineering, becoming both a biomedical engineer and professor of ophthalmology. Dr. Humayun led a talented and diverse team of interdisciplinary researchers with the ultimate goal of creating the world's first artificial retina. He assembled a team of world experts with a wide range of proficiency, including biomedical engineering, computer science, medicine, chemistry, biology, and business. In clinical trials since 2007 and approved by the FDA in 2013, the Argus II retinal implant, represents the culmination of a visual restoration strategy that offers an unprecedented degree of sight to those with complete retinal blindness. He was elected to the prestigious National Academy of Medicine (NAM) and National Academy of Engineering (NAE) for his pioneering work to restore sight. With over 200 publications and more than 100 patents and patent applications, Dr. Humayun has received several research awards, which include the 2005 Innovator of the Year award. He was also featured as one of the top 10 inventors in Time Magazine in 2013, voted as one of the Best Doctors in America for three years, and one of the top 1% of Doctors by U.S. News & World Report. In 2016, Dr. Humayun received the National Medal of Technology and Innovation from President Barack Obama for his innovative work and development of the Argus II. Host Bio: Dr. Calvin W. Roberts Calvin W. Roberts, MD, is President and Chief Executive Officer of Lighthouse Guild, the leading organization dedicated to providing exceptional services that inspire people who are visually impaired to attain their goals. Dr. Roberts has a unique blend of academic, clinical, business, and hands-on product development experience. Dr. Roberts is a Clinical Professor of Ophthalmology at Weill Cornell Medical College. He was formerly Senior Vice President and Chief Medical Officer, Eye Care, at Bausch Health Companies where he coordinated global development and research efforts across their vision care, pharmaceutical, and surgical business units. As a practicing ophthalmologist from 1982 to 2008, he performed more than 10,000 cataract surgeries as well as 5,000 refractive and other corneal surgeries. He is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens. He also holds patents on the wide-field specular microscope and has done extensive research on ophthalmic non-steroidals and postoperative cystoid macular edema. Dr. Roberts has co-founded a specialty pharmaceutical company and is a frequent industry lecturer and author. He currently serves as an Independent Director on multiple corporate boards and has served as a consultant to Allergan, Johnson & Johnson, and Novartis. A graduate of Princeton University and the College of Physicians and Surgeons of Columbia University, Dr. Roberts completed his internship and ophthalmology residency at New York-Presbyterian Hospital/Columbia University Medical Center in New York. He also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston.

Vision problems have always affected humanity, but until the invention of eyeglasses, there wasn't much that could be done. Now, with lasers, retinal implants, AR, gene therapy and more, we may have the technology it takes to permanently solve many vision problems. Featuring innovators like Mike Marmor, Lisa Nijm, Mark Humayun, Drew Perkins and Jean Bennett.  For more on the podcast go to delltechnologies.com/trailblazers

This week marks the official launch of the OIS Retina Podcast with host Firas Rahhal, MD, interviewing world-renowned retina specialist and serial inventor Mark Humayun, MD, PhD, as his first guest. Here are a few impressive facts about Dr. Humayun:• He’s the director of the Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics at the University of Southern California and co-director of the USC Roski Eye Institute.• He’s a professor of ophthalmology and a biomedical engineer.• He received numerous research awards, including the 2005 Innovator of the Year Award.• He was featured as one of the Top 10 Inventors by Time magazine in 2013.• In 2016 he received the National Medal of Technology and Innovation from President Barack Obama for his innovative work on the Argus retinal prosthesis.• He was awarded the 2020 Medal for Innovations in Healthcare Technology by the Institute of Electrical and Electronics Engineers.• He’s written over 200 publications and filed over 100 patents.• He’s been consistently voted as One of the Top Doctors in the World.• He was once a guest on the Howard Stern Show!Listen in to hear how Dr. Rahhal compares to the King of All Media.

Dr. Mark Humayun discusses the results of his team's work on implantation of RPE stems cells placed on a bioengineered surface for dry AMD.  Full reference of the article: Kashani, A. H., Lebkowski, J. S., Rahhal, F. M., Avery, R. L., Salehi-Had, H., Dang, W., . . . Humayun, M. S. (2018). A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med, 10(435). doi:10.1126/scitranslmed.aao4097

Over two decades ago, Mark Humayun – who will co-chair our upcoming OIS@ASRS meeting in San Francisco – helped launch a “moonshot” that would eventually restore vision for retinitis pigmentosa patients. In this podcast we discuss what drives him and what’s next for ophthalmology.

Robert Dempsey joined Shire to build a new ophthalmology unit. Until now, the division had been mostly theoretical with no products to sell. Now, the brand building is over. Shire officially has entered the ophthalmology sector with the launch of its potential blockbuster, Xiidra. Hear what’s next for the Dry Eye treatment and what else we can expect to see from Shire’s pipeline.

Over two decades ago, Mark Humayun - who will co-chair our upcoming OIS@ASRS - helped launch a “moonshot” that would eventually restore vision for retinitis pigmentosa patients. In this podcast we discuss what drives him and what’s next for ophthalmology.

Host: Roy Levit, MD Guest: Mark Humayun, MD Microelectronic implants are restoring vision to the blind.Dr. Mark Humayun discusses with host Dr. Roy Levit the workings of the artificial retina and explains the surgical procedure to implant the device in the eye. The first generation of the implant only has 16 pixels while the second generation has 62 pixels. Dr. Humayun explains how the subjects who have the implant can initially see spots of light, but that the brain over time can fill in the details and many patients are able to see objects, motion and color. At this time, the implants are available only as a part of the clinical trial to subjects who are completely blind as a result of retinitis pigmentosa.